BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 9, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2001

View Archived Issues

ArQule and Camitro agree to merge

Read More

Cambridge Drug Discovery and Teijin alliance makes progress

Read More

Tamoxifen for breast cancer prevention does not alter cardiovascular risk

Read More

Potential of telomerase inhibitors for chemoprevention emerges from recent research

Read More

Antibacterial eyedrops to be jointly developed by SSP and InSite

Read More

New ROCK inhibitor with potential for the treatment of glaucoma licensed out by Welfide

Read More

Research at Johns Hopkins provides proof of concept for gene therapy of cardiac arrhythmias

Read More

Virco and Tibotec announce merger

Read More

NDA filed in U.S. for once-daily Xatral

Read More

FDA issues approval letter for Axcan's Canasa for ulcerative proctitis

Read More

Caspase inhibitors show potential for reducing myocyte death

Read More

Andrx begins basic research program for the use of statins in Alzheimer's disease

Read More

Donitriptan expected to represent significant step forward in acute migraine therapy

Read More

Results with extended-release ciprofloxacin product promising, reports DepoMed

Read More

First IVR-based product for HRT advances toward market launch

Read More

Emisphere seeks FDA clearance to begin trials of new drug delivery agent for heparins

Read More

Molecular Templates: new company focused on anticancer agents

Read More

TKR-2993: new antifungal antibiotic identified by Takara Shuzo

Read More

Cardiovascular and metabolic effects of LY-117018 explored in rat model

Read More

Potent inhibitors of phosphodiesterase type 4 described by Euroceltique

Read More

New agents described by Kyorin for lowering lipid levels

Read More

Introgen awarded SBIR grant to study INGN-241 as lung cancer treatment

Read More

Syk inhibitors and their use claimed by Yamanouchi

Read More

New leucomycin derivatives under study as antibacterials at Meiji Seika

Read More

Patent issued to Welfide covering new series of potential antidepressants

Read More

Mutual salts, prodrugs of amlodipine and atorvastatin and their use

Read More

Collateral Therapeutics gains option to UCSF cell cycle regulation technology

Read More

Human growth-promoting compound optioned by Atrix from Tulane University

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 8, 2025.
  • Mesothelin is biomarker, potential target in arthritic bone damage

    BioWorld Science
    In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing